Amyotrophic lateral sclerosis research appropriation provision and appropriation cancellation provision

SF 3155 cancels $15 million in previously allocated funds for ALS research and appropriates $15 million from the general fund for a one-time collaborative research partnership between the University of Minnesota Board of Regents and the Mayo Clinic. This funding supports ongoing ALS research with the goal of improving lives for those affected and finding a cure, directly impacting researchers at these institutions. The bill requires the University of Minnesota to submit annual reports starting January 2026 detailing how funds are used until 2030 or when fully expended. It repeals the prior ALS research appropriation law (Laws 2022, chapter 42, section 2) that had managed smaller, multi-year grant programs.